

8.01.26 Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Original Policy Date:	January 7, 2011	Effective Date:	April 1, 2024
Section:	11.0 Transplant	Page:	Page 1 of 27

Policy Statement

- I. Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered **medically necessary** to treat **any** of the following conditions:
 - A. Poor- to intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) (see Policy Guidelines section for information on risk stratification)
 - B. AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy
 - C. AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy
 - D. AML in individuals who have relapsed following a prior autologous HCT but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure
- II. Allogeneic HCT using a reduced-intensity conditioning regimen may be considered **medically necessary** as a treatment of AML in individuals who are in complete marrow and extramedullary remission (CR1 or beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines section).
- III. Autologous HCT may be considered **medically necessary** to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy in individuals who are not candidates for allogeneic HCT.
- IV. Allogeneic and autologous HCT are considered **investigational** in individuals not meeting any of the above criteria.

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Primary refractory acute myeloid leukemia (AML) is defined as leukemia that does not achieve a complete remission after conventionally dosed (nonmarrow ablative) chemotherapy.

In the French-American-British criteria, the classification of AML is solely based on morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.

Clinical features that predict poor outcomes of AML therapy include, but are not limited to, the following:

- Treatment-related AML (secondary to prior chemotherapy and/or radiotherapy for another malignancy)
- AML with antecedent hematologic disease (e.g., myelodysplasia)
- Presence of circulating blasts at the time of diagnosis
- Difficulty in obtaining first complete remission with standard chemotherapy
- Leukemias with monocytoid differentiation (French-American-British classification M4 or M5)

World Health Organization Classification

The newer, currently preferred, World Health Organization (WHO) classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers. It

attempts to construct a classification that is universally applicable and prognostically valid. The World Health Organization system was adapted by National Comprehensive Cancer Network (NCCN) to estimate individual prognosis to guide management, as shown in Table PG1.

Table PG1. Risk Status of AML Based on Genetic Factors

Risk Category	Genetic Abnormality
Favorable	t(8;21)(q22;q22.1); <i>RUNX1-RUNX1T1</i> inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); <i>CBFB-MYH11</i> Biallelic mutated <i>CEBPA</i> Mutated <i>NPM1</i> without <i>FLT3</i> -ITD or with <i>FLT3</i> -ITD ^{low}
Intermediate	Mutated <i>NPM1</i> and <i>FLT3</i> -ITD ^{high} Wild-type <i>NPM1</i> without <i>FLT3</i> -ITD or with <i>FLT3</i> -ITD ^{low} (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); <i>MLL-T3-KMT2A</i> Cytogenetic abnormalities not classified as favorable or adverse
Poor/Adverse	t(6;9)(p23;q34.1); <i>DEK-NUP214</i> t(v;11q23.3); <i>KMT2A</i> rearranged t(9;22)(q34.1;q11.2); <i>BCR-ABL1</i> inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); <i>GATA2, MECOM(EV1)</i> -5 or del(5q); -7; -17/abn(17p) Complex karyotype, monosomal karyotype Wild-type <i>NPM1</i> and <i>FLT3</i> -ITD ^{high} Mutated <i>RUNX1</i> (if not co-occurring with favorable-risk AML subtypes) Mutated <i>ASXL1</i> (if not co-occurring with favorable-risk AML subtypes) Mutated <i>TP53</i>

AML: acute myeloid leukemia; ITD: internal tandem duplication.

The relative importance of cytogenetic and molecular abnormalities in determining prognosis and guiding therapy is under investigation.

The ideal allogeneic donors are human leukocyte antigen (HLA)-identical siblings, matched at the HLA-A, -B, and -DR (antigen-D related) loci (6 of 6). Related donors mismatched at 1 locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the individual, for which there usually is sharing of only 3 of the 6 major histocompatibility antigens. Most individuals will have such a donor; however, the risk of graft-versus-host disease and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.

Coding

In 2003, CPT centralized codes describing allogeneic and autologous hematopoietic cell support services to the hematology section (CPT 38204–38242). Not all codes are applicable for each stem cell support procedure. For example, Plans should determine if cryopreservation is performed. A range of codes describe services associated with cryopreservation, storage, and thawing of cells (38208–38215).

Thawing and washing of cryopreserved cells:

- **38208:** Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
- **38209:** Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor

Types of cells being depleted:

- **38210:** Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion
- **38211:** Transplant preparation of hematopoietic progenitor cells; tumor cell depletion

- **38212:** Transplant preparation of hematopoietic progenitor cells; red blood cell removal
- **38213:** Transplant preparation of hematopoietic progenitor cells; platelet depletion
- **38214:** Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion

Plasma cell concentration:

- **38215:** Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer

Description

Acute myeloid leukemia (AML) refers to leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into various post-remission strategies using either allogeneic (allo-) or autologous hematopoietic cell transplantation (HCT). Hematopoietic cell transplantation refers to a procedure that infuses hematopoietic stem cells to restore bone marrow function in cancer patients who receive bone marrow-toxic doses of drugs with or without whole-body radiotherapy.

Related Policies

- N/A

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale

Background

Acute Myeloid Leukemia Treatment

Complete remission of acute myeloid leukemia (AML) can be achieved initially using induction therapy, consisting of conventional doses of combination chemotherapy. A complete response is achieved in 60% to 80% of adults younger than 60 years of age and 40% to 60% in patients older than 60 years of age. However, the high incidence of disease relapse has prompted research into a variety of post-remission (consolidation) strategies, typically using high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) or high-dose or reduced-intensity chemotherapy with allogeneic HCT (allo-HCT). The 2 treatments, autologous HCT and allo-HCT,

represent 2 different strategies. The first, autologous HCT, is a “rescue,” but not a therapeutic procedure; the second, allo-HCT, is a “rescue” plus a therapeutic procedure.

Hematopoietic Cell Transplantation

Hematopoietic cell transplantation is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy.

Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allo-HCT). These cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allo-HCT, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. Human leukocyte antigen refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

Conditioning for Hematopoietic Cell Transplantation

Conventional Conditioning

The conventional (“classical”) practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease (GVHD), which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning (MAC) treatments. Although the definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and nonrelapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and nonrelapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Reduced-intensity conditioning regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed

chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term RIC will refer to all conditioning regimens intended to be nonmyeloablative.

A 2015 review in the *New England Journal of Medicine* summarized advances in the classification of AML, the genomics of AML and prognostic factors, and current and new treatments.¹ The National Comprehensive Cancer Network guidelines provide updated information on genetic markers for risk stratification, and additional recent reviews summarize information on novel therapies for AML.^{2,3,4}

Literature Review

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Allogeneic Hematopoietic Stem Cell Transplant with Myeloablative Conditioning for Cytogenetic or Molecular Intermediate- or Poor-Risk AML in Complete Remission

Clinical Context and Therapy Purpose

The purpose of allogeneic (allo-) hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in individuals who have cytogenetic or molecular intermediate- or poor-risk acute myeloid leukemia (AML) in first complete remission (CR1) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with cytogenetic or molecular intermediate- or poor-risk AML in CR1.

Interventions

The therapy being considered is allo-HCT with MAC. Allogeneic HCT with MAC is an option for post-remission or consolidation therapy in cytogenetic or molecular intermediate- or poor-risk AML. The

purpose of post-remission therapy is to destroy undetectable leukemia cells remaining after induction chemotherapy.

Comparators

The following therapies are currently being used to make decisions about cytogenetic or molecular intermediate- or poor-risk AML in CR1: conventional chemotherapy.

Outcomes

The general outcomes of interest are survival outcomes (overall survival [OS], disease-specific survival [DSS], and disease-free survival [DFS]), relapse rates, and treatment-related morbidity. The median survival of individuals with AML varies with several known prognostic factors related to individual and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for individuals with AML without chemotherapy or HCT is less than 10 months; the median survival in patients with chemotherapy but without HCT is approximately 20 months.⁵ Individuals are followed up throughout their lifespan.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Systematic Reviews

Masetti et al (2022) conducted a meta-analysis of allo-HCT for pediatric patients with AML in CR1.⁶ Both prospective and retrospective studies comparing allo-HCT to chemotherapy in higher-risk patients were considered. A total of 9 studies (5 prospective, 4 retrospective) were included; none of the prospective studies were randomized. The meta-analysis showed that OS was improved with allo-HCT compared with chemotherapy (risk ratio, 1.15; 95% confidence interval [CI], 1.06 to 1.24; $P=0\%$). Similarly, DFS was improved with allo-HCT compared to chemotherapy (risk ratio, 1.31; 95% CI, 1.17 to 1.47; $P=1\%$). Risk of relapse was higher among patients who received chemotherapy (risk ratio, 1.26; 95% CI, 1.07 to 1.49; $P=23\%$).

A 2015 meta-analysis examined prospective trials of adults with intermediate-risk AML in CR1 who underwent HCT.⁷ The analysis included 9 prospective, controlled studies that enrolled 1950 patients between the years 1987 and 2011 (sample range, 32 to 713 patients). In this meta-analysis, allo-HCT was associated with significantly better relapse-free survival (RFS), OS, and relapse rate than autologous HCT and/or chemotherapy (hazard ratio [HR], 0.68; 95% CI, 0.48 to 0.95; HR, 0.76; 95% CI, 0.61 to 0.95; HR, 0.58; 95% CI, 0.45 to 0.75, respectively). Treatment-related mortality was significantly higher following allo-HCT than autologous HCT (HR, 3.09; 95% CI, 1.38 to 6.92). However, a subgroup analysis, which used updated criteria to define intermediate-risk AML, showed no OS benefit for allo-HCT over autologous HCT (HR, 0.99; 95% CI, 0.70 to 1.39).

A 2009 systematic review incorporated data from 24 trials involving 6007 patients who underwent allo-HCT in CR1.⁸ Among the total, 3638 patients were stratified and analyzed according to cytogenetic risk (547 good-, 2499 intermediate-, 592 poor-risk patients with AML) using a fixed-effects model. Compared with either autologous HCT or additional consolidation chemotherapy, the HR for OS among poor-risk patients across 14 trials was 0.73 (95% CI, 0.59 to 0.90; $p<.01$); among intermediate-risk patients across 14 trials, the HR for OS was 0.83 (95% CI, 0.74 to 0.93; $p<.01$); and among good-risk patients across 16 trials, the HR for OS was 1.07 (95% CI, 0.83 to 1.38;

$p=.59$). Interstudy heterogeneity was not significant in any of these analyses. Results for DFS were very similar to those for OS in this analysis. These results are in line with those from another meta-analysis⁹ on the use of allo-HCT as consolidation therapy for AML.

A 2005 meta-analysis of allo-HCT in patients with AML in CR1 pooled data from 5 studies (N=3100 patients).⁹ Among those patients, 1151 received allo-HCT, and 1949 were given alternative therapies including chemotherapy and autologous HCT. All studies employed natural randomization based on donor availability and intention-to-treat analysis, with OS and DFS as outcomes of interest. This analysis showed a significant advantage for allo-HCT regarding OS for the entire cohort (fixed-effects model HR, 1.17; 95% CI, 1.06 to 1.30; $p=.003$; random-effects model HR, 1.15; 95% CI, 1.01 to 1.32; $p=.037$) even though none of the individual studies did so. Meta-regression analysis showed the effect of allo-HCT on OS differed depending on the cytogenetic risk groups of patients, suggesting a significant benefit for poor-risk patients (HR, 1.39, 95% CI not reported), an indeterminate benefit for intermediate-risk cases, and no benefit in better-risk patients compared with alternative approaches. Reviewers cautioned the compiled studies used different definitions of risk categories than other groups (e.g., SWOG, Medical Research Council, European Organisation for Research and Treatment of Cancer, Gruppo Italiano Malattie Ematologiche dell' Adulto).¹⁰ Although the statistical power of the meta-regression analysis was limited by small numbers of cases, the results of this meta-analysis are supported in general by data from other reviews.^{11,12,13,14}

Evidence from the meta-analysis suggests patients with better prognosis (as defined by cytogenetics) may not realize a significant survival benefit with allo-HCT in CR1 that outweighs the risk of associated morbidity and nonrelapse mortality. However, there is considerable genotypic heterogeneity within the 3 World Health Organization cytogenetic prognostic groups that complicates generalization of clinical results based only on cytogenetics.¹⁵ For example, patients with better prognosis disease (e.g., core-binding factor AML) based on cytogenetics, and a variant in the *KIT* gene of leukemic blast cells, do just as poorly with post-remission standard chemotherapy as patients with cytogenetically poor-risk AML.¹⁶ Similarly, patients with cytogenetically normal AML (intermediate prognosis disease) can be subcategorized into groups with better or worse prognosis based on the mutational status of the nucleophosmin gene (*NPM1*) and the *FLT3* gene (the *FLT3* gene is a gene that encodes FMS-like receptor tyrosine kinase 3, a growth factor active in hematopoiesis). Thus, patients with variants in *NPM1* but without *FLT3* internal tandem duplications have post-remission outcomes with standard chemotherapy that are similar to those with better prognosis cytogenetics. In contrast, patients with any other combination of variants in those genes have outcomes similar to those with poor prognosis cytogenetics.¹⁷ It follows that, because the earlier clinical trials compiled in the meta-analysis described here did not account for genotypic differences that affect prognosis and alter outcomes, it is difficult to use the primary trial results to draw conclusions on the role of allo-HCT in different patient risk groups.

A meta-analysis by Buckley et al (2017) evaluated the relationship between minimal residual disease (MRD) at the time of HCT and posttransplantation outcomes.¹⁸ The literature search, conducted through June 2016, identified 19 studies (N=1431 patients) for inclusion. Risk of bias was assessed using a modified version of the Quality of Prognostic Studies instrument, which focused on: prognostic factor measurement, study confounding, and statistical analysis and reporting. Five studies were considered at high-risk for bias, 9 were at moderate-risk, and 5 were at low-risk. The following variables were collected from each study: age, follow-up, adverse-risk cytogenetics, conditioning type (myeloablative or reduced-intensity), MRD detection method, and survival. Reviewers reported that the presence of MRD at the time of transplantation was associated with higher relapse and mortality. This association was seen regardless of patient age and type of conditioning, which suggests that an intense conditioning regimen may not be able to overcome the adverse impact of MRD.

Prospective Studies

Bornhäuser et al (2023) conducted an open-label, 2-arm, multicenter RCT in Germany to assess the ideal postremission strategy in intermediate-risk AML in CR1.¹⁹ Adults with AML (age 18 to 60 years) in CR1 or CR with incomplete blood cell count recovery after conventional induction therapy who had availability of a human leukocyte antigen-matched sibling or unrelated donor were included and randomized 1:1 to receive allo-HCT or high-dose cytarabine (HiDAC) for consolidation and salvage HCT only in cases of relapse. The primary outcome was OS, DFS, incidence of relapse, treatment-related mortality, and quality of life measures according to the Medical Outcomes Study 36-Item Short-Form Health Survey were secondary outcomes. One hundred forty-three patients (mean age, 48.2 years, standard deviation, 9.8 years; 57% male) with AML were randomized. At 2 years, the probability of survival was 74% (95% CI, 62% to 83%) after primary allo-HCT and 84% (95% CI, 73% to 92%) after HiDAC ($p=.22$). Disease-free survival at 2 years was 69% (95% CI, 57% to 80%) after HCT compared with 40% (95% CI, 28% to 53%) after HiDAC ($p=.001$). The cumulative incidence of relapse at 2 years with allo-HCT was 20% (95% CI, 13% to 31%) compared with 58% (95% CI, 47% to 71%; $p<.001$) with HiDAC and nonrelapse mortality after allo-HCT was 9% (95% CI, 5% to 19%) versus 2% (95% CI, 0% to 11%) after HiDAC ($p=.005$). All 41 participants who relapsed after HiDAC proceeded to receive allo-HCT. There were no differences in quality of life measures between groups. Of note, this trial was closed earlier than anticipated due to slow patient accrual, which was a limitation. Additional limitations included the lack of stratification based on MRD and the use of a cytogenetic classifier at trial initiation (2012) which led to inclusion of some favorable-risk patients, which current guidelines would not recommend allo-HCT in CR1. In conclusion, primary allo-HCT during CR1 was not associated with superior OS compared to HiDAC in adults with intermediate-risk AML <60 years, although some secondary endpoints had promising results and were hypothesis generating.

A 2014 study compared outcomes of 185 matched pairs from a large multicenter trial (AMLCG99).²⁰ Patients younger than 60 years of age who underwent allo-HCT in CR1 were matched to patients who received conventional post-remission chemotherapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in CR1. In the overall pairwise-compared AML population, the projected 7-year OS rate was 58% for allo-HCT and 46% for the conventional post-remission treatment group ($p=.037$). The RFS rate was 52% in the allo-HCT group and 33% in the control group ($p<.001$). The OS was significantly longer for allo-HCT patient subgroups with unfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, post-remission therapy was an independent factor for OS (HR, 0.66; 95% CI, 0.49 to 0.89 for allo-HCT vs. conventional chemotherapy) among age, cytogenetics, and bone marrow blasts after the first induction cycle.

Retrospective Studies

Heidrich et al (2017) conducted retrospective analyses of subgroups from 2 prospective clinical trials, including 497 patients with intermediate-risk AML who did not present with *NPM1*, *CEBPA*, or *FLT3* internal tandem duplication variants.²¹ During the initial analysis (donor vs. no-donor), RFS rates were better for patients who had an available sibling donor ($n=83$) than for those who lacked a matched sibling donor (49% vs. 26%; HR, 0.5; 95% CI, 0.3 to 0.9; $p=.02$). A similar improvement was seen for OS, although not statistically significant ($p=.08$). The authors also conducted a time-dependent multivariate analysis to account for the significantly longer time-from-CR1 observed in patients treated with allo-HCT (median, 115 days) compared with those treated with post-remission chemotherapy (median, 78 days; $p<.001$). Rates of OS after 5 years were superior for the group who received allo-HCT than for those receiving chemotherapy (OS, 66% vs. 46%, respectively; HR, 0.58; 95% CI, 0.37 to 0.9; $p=.02$), as were rates of RFS (5-year RFS, 55% vs. 31%; HR, 0.51; 95% CI, 0.34 to 0.76; $p=.001$). The investigators acknowledged that 38% of the group assigned to post-remission chemotherapy received allo-HCT following a relapse, which might have contributed to a crossover effect.

Section Summary: Allogeneic Hematopoietic Cell Transplant with Myeloablative Conditioning for Cytogenetic or Molecular Intermediate- or Poor-Risk AML in Complete Remission

Evidence for the use of allo-HCT for patients with AML in CR1 consists of systematic reviews, RCTs, and matched cohort studies. Some studies have compared allo-HCT with autologous HCT or with post-remission chemotherapy. In some studies, the OS and DFS rates were favorable for allo-HCT compared with conventional chemotherapy. In a paired comparison with patients receiving chemotherapy, patients receiving allo-HCT experienced significantly higher RFS rates. However, in a more recent RCT, there was no difference in OS between allo-HCT and HiDAC, although there were many limitations associated with this study. Two retrospective studies analyzed subgroups of allo-HCT patients who did not present with several common genetic variants or who presented with hyperleukocytosis. Survival rates appear to be associated with the presence of MRD and cytogenetic prognosis groups.

Allogeneic HCT with Myeloablative Conditioning for AML Refractory to Standard Induction Chemotherapy

Clinical Context and Therapy Purpose

The purpose of allo-HCT with MAC in individuals who have AML refractory to standard induction chemotherapy is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population(s) of interest is individuals with AML refractory to standard induction chemotherapy.

Interventions

The therapy being considered is allo-HCT with MAC. Allogeneic HCT is an option for AML refractory to standard induction chemotherapy. The purpose is to destroy leukemia cells remaining after induction chemotherapy.

Comparators

The following therapies are currently being used to make decisions about AML refractory to standard induction chemotherapy: conventional chemotherapy.

Outcomes

The general outcomes of interest are survival outcomes (OS, DSS, and DFS), relapse rates, and treatment-related morbidity. The median survival of individuals with AML varies with several known prognostic factors related to individual and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for individuals with AML without chemotherapy or HCT is less than 10 months; the median survival in patients with chemotherapy but without HCT is approximately 20 months.⁵ Individuals are followed up throughout their lifespan.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Retrospective Studies

Conventional dose induction chemotherapy will not produce remission in 20% to 40% of patients with AML, connoting refractory AML.¹⁰ An allo-HCT using a matched related donor or matched unrelated donor represents the only potentially curative option for these patients. In several retrospective studies, OS rates have ranged from 30% at 3 years to 13% at 5 years, although this procedure is accompanied by nonrelapse mortality rates of 25% to 62% in this setting.¹¹ A 2022 observational study reported higher 3-year and 5-year OS (38% and 33%, respectively), but these rates may lack precision due to a small sample size (N=12).²² Another small study reported 4-year OS of 51.0±10.6% among 29 patients who received allo-HCT and 46.2±9.0% among 34 patients who received salvage chemotherapy followed by allo-HCT, both for refractory AML.²³ For patients who lack a suitable donor (matched related donor or matched unrelated donor), alternative treatments include salvage chemotherapy with high-dose cytarabine or etoposide-based regimens, monoclonal antibodies (e.g., gemtuzumab ozogamicin), *FLT3* antagonists, *IDH1/IDH2* inhibitors, and clinical trial enrollment.² Because it is likely that stem cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, upfront autologous HCT has no role in patients who fail induction therapy.²⁴

Section Summary: Allogeneic HCT with Myeloablative Conditioning for AML Refractory to Standard Induction Chemotherapy

Evidence for the use of allo-HCT for individuals with primary AML refractory to chemotherapy consists of retrospective studies compiled from data from phase 3 trials and registries. The OS rate estimates range from 30% to 38% at 3 years and 13% to 51% at 4 to 5 years; however, the procedure is accompanied by high rates of nonrelapse mortality (estimated range, 25% to 62%). Nonetheless, these results may provide a clinically meaningful benefit for such patients who do not have other treatment options. Autologous HCT is not recommended for patients who have failed induction therapy, because malignant cells may be included in the stem cell preparation process.

Allogeneic or Autologous HCT with Myeloablative Conditioning for Relapsed AML After Chemotherapy-Induced Remission

Clinical Context and Therapy Purpose

The purpose of allogeneic or autologous HCT with MAC in individuals who have relapsed AML after standard induction chemotherapy-induced CR1 is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population(s) of interest is individuals with AML who relapsed after standard induction chemotherapy-induced CR1.

Interventions

The therapy being considered is allo-HCT or autologous HCT. Allogeneic or autologous HCT are options for treatment of relapsed AML after chemotherapy-induced remission. The purpose of HCT is to destroy leukemia cells associated with recurrent AML.

Comparators

The following therapies are currently being used to make decisions about relapsed AML after chemotherapy-induced remission: conventional chemotherapy.

Outcomes

The general outcomes of interest are survival outcomes (OS, DSS, and DFS), relapse rates, and treatment-related morbidity. The median survival of individuals with AML varies with several known

prognostic factors related to individual and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for patients with AML without chemotherapy or HCT is less than 10 months; the median survival in individuals with chemotherapy but without HCT is approximately 20 months.⁵ Individuals are followed up throughout their lifespan.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Retrospective Studies

Most patients with AML will experience disease relapse after attaining a CR1.¹⁰ Conventional chemotherapy is not curative in most patients following disease relapse, even if a second complete remission (CR2) can be achieved.

A study by Breems et al (2005) evaluated retrospective data from 667 patients who had relapsed, among a total of 1540 patients entered in 3, phase 3 trials who had received HCT during CR1. The analysis suggested that use of allo-HCT among relapsed patients can produce 5-year OS rates of 26% to 88%, depending on cytogenetic risk stratification.²⁵

Allo-HCT is often performed as salvage therapy for patients who have relapsed after conventional chemotherapy or autologous HCT.²⁴ The decision to attempt reinduction to allo-HCT is based on the availability of a suitable stem cell donor and the likelihood of achieving remission, the latter being a function of cytogenetic risk group, duration of CR1, and the patient's health status. Registry data have shown DFS rates of 44% using sibling allografts and 30% with matched unrelated donor allografts at 5 years for patients transplanted in CR2, and DFS rates of 35% to 40% using sibling transplants and 10% with matched unrelated donor transplants for patients with induction failure or in relapse following HCT.²⁴

In a retrospective chart review, Frazer et al (2017) assessed characteristics that might predict OS, relapse rate, and nonrelapse mortality of HCT in patients with relapsed AML.²⁶ Data were abstracted from 55 consecutive patients who underwent allo-HCT for AML in CR2. The OS rates at 1, 3, and 5 years posttransplant were 60%, 45%, and 37%, respectively. None of the following pretransplant variables were significantly associated with OS, relapse rate, or nonrelapse mortality: duration of first remission, patient age, cytogenetic risk category, post myelodysplastic syndrome, conditioning regimen, or donor type. Limitations of the study were its small sample size and selection parameters that included transplantations conducted across 21 years.

In patients in CR2 without an allogeneic donor or who are not candidates for allo-HCT due to age or other factors, autologous HCT may achieve prolonged DFS in 9% to 55% of patients in CR2 depending on risk category.^{24,27} However, because it is likely that stem cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, and it is often difficult to achieve CR2 in these patients, autologous HCT in this setting is usually limited to patients who have a sufficient stem cell preparation remaining from the collection in CR1.²⁴

Section Summary: Allogeneic or Autologous HCTR with Myeloablative Conditioning for Relapsed AML After Chemotherapy-Induced Remission

Evidence on the use of HCT for individuals with relapsed AML includes retrospective chart reviews compiling data from phase 3 trials and registries. The DFS rates ranged from 30% to 44% depending on the source of transplantation cells, and OS rates ranged from 26% to 88% depending on risk stratification. Because reinduction chemotherapy may be associated with high morbidity and mortality, HCT may be considered.

Allogeneic HCT With Reduced-Intensity Conditioning for Cytogenetic or Molecular Intermediate- or Poor-Risk AML in Remission

Clinical Context and Therapy Purpose

The purpose of allo-HCT with reduced-intensity conditioning (RIC) in individuals who have cytogenetic or molecular intermediate- or poor-risk AML in CR1 who cannot tolerate MAC is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population(s) of interest is individuals with cytogenetic or molecular intermediate- or poor-risk AML in CR1 who cannot tolerate MAC.

Interventions

The therapy being considered is allo-HCT with RIC. Allogeneic HCT with RIC is an option for post-remission therapy for cytogenetic or molecular intermediate- or poor-risk AML. The purpose of post-remission therapy is to destroy undetectable leukemia cells remaining after induction chemotherapy.

Comparators

The following therapies are currently being used to make decisions about cytogenetic or molecular intermediate- or poor-risk AML in CR1: conventional chemotherapy and allo-HCT with MAC.

Outcomes

The general outcomes of interest are survival outcomes (OS, DSS, and DFS), relapse rates, and treatment-related morbidity. The median survival of individuals with AML varies with several known prognostic factors related to individual and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for individuals with AML without chemotherapy or HCT is less than 10 months; the median survival in patients with chemotherapy but without HCT is approximately 20 months.⁵ Individuals are followed up throughout their lifespan.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

A body of evidence is accruing from clinical studies that RIC with allo-HCT may be used for consolidation therapy in patients with AML.^{28,-,39,}

Systematic Reviews

Song et al (2021) evaluated the efficacy of RIC followed by allo-HCT in patients with AML and myelodysplastic syndrome via a meta-analysis of 6 RCTs (N=1413).⁴⁰ The 6 RCTs compared RIC to MAC before first allo-HCT in patients with AML in complete remission or myelodysplastic syndrome. The primary endpoint was OS. Results revealed that OS was not significantly different between RIC and MAC (HR, 0.95; 95% CI, 0.64 to 1.4; $p=.80$). The cumulative incidence of relapse was also similar between the groups (HR, 1.18; 95% CI, 0.88 to 1.49; $p=.28$). Nonrelapse mortality was significantly improved with RIC as compared to total body irradiation/busulfan-based MAC (HR, 0.53; 95% CI, 0.36 to 0.8; $p=.002$); however, treosulfan-based MAC significantly reduced nonrelapse mortality as compared to RIC (HR, 1.67; 95% CI, 1.02 to 2.72; $p=.04$). Reduced-intensity conditioning was associated with a trend of increasing graft failure ($p=.06$); however, graft failure in both arms was rare. The authors concluded that RIC is recommended as an adequate option of preparative treatment before allo-HCT for patients with AML in complete remission or myelodysplastic syndrome. Limitations of the meta-analysis included the small number of included clinical trials, significant heterogeneity between included studies for some outcomes, and lack of blinding in some studies.

A systematic review and meta-analysis by Rashidi et al (2016) calculated OS and RFS for patients older than 60 years of age with AML who underwent RIC HCT.⁴¹ A literature search, conducted through September 2015, identified 13 studies (N=749 patients) for inclusion. Pooled estimates for RFS at 6 months, 1 year, 2 years, and 3 years were 62% (95% CI, 54% to 69%), 47% (95% CI, 42% to 53%), 44% (95% CI, 33% to 55%), and 35% (95% CI, 26% to 45%), respectively. Pooled estimates for OS at 6 months, 1 year, 2 years, and 3 years were 73% (95% CI, 66% to 79%), 58% (95% CI, 50% to 65%), 45% (95% CI, 35% to 54%), and 38% (95% CI, 29% to 48%), respectively.

A 2014 meta-analysis compared RIC with MAC regimens for allo-HCT in patients with AML.⁴² The analysis included 23 clinical trials reported between 1990 and 2013, with approximately 15,000 adults. Eleven studies included AML and myelodysplastic syndrome, and 5 included AML only. A subanalysis from 13 trials in patients with AML or myelodysplastic syndrome revealed that OS was comparable in patients who received either RIC or MAC transplants, and the 2-year or less and 2-year or greater OS rates were equivalent between both conditioning groups. The 2- to 6-year progression-free survival, nonrelapse mortality, and acute and chronic graft-versus-host disease (GVHD) rates were reduced after RIC HCT, but the relapse rate was increased. Similar outcomes were observed regardless of disease status at transplantation. Among the RIC HCT recipients, survival rates were superior if patients were in CR at transplantation.

Randomized Controlled Trials

A randomized comparative trial in matched patient groups compared the net health benefit of allo-HCT with RIC or with MAC.^{43,44,45} In this phase 3 trial, patients (18 to 60 years) were randomized to 4 doses of RIC (n=99) at 2 gray of total body irradiation plus fludarabine 150 mg/m², or to 6 doses of standard conditioning (n=96) at 2 gray of total body irradiation plus cyclophosphamide 120 mg/kg. All patients received cyclosporine and methotrexate as prophylaxis against GVHD. The primary endpoint was the incidence of nonrelapse mortality analyzed in the intention-to-treat population. This unblinded trial was stopped early because of slow accrual of patients. The incidence of nonrelapse mortality did not differ between the RIC and standard conditioning groups (cumulative incidence at 3 years, 13% [95% CI, 6% to 21%] vs. 18% [95% CI, 10% to 26%]; HR, 0.62; 95% CI, 0.30 to 1.31, respectively). Relapse cumulative incidence at 3 years was 28% (95% CI, 19% to 38%) in the RIC group and 26% (95% CI, 17% to 36%; HR, 1.10; 95% CI, 0.63 to 1.90) in the standard conditioning group. The DFS rates at 3 years were 58% (95% CI, 49% to 70%) in the RIC group and 56% (95% CI, 46% to 67%; HR, 0.85; 95% CI, 0.55 to 1.32) in the standard conditioning group. The OS rates at 3 years were 61% (95% CI, 50% to 74%) in the RIC group and 58% (95% CI, 47% to 70%; HR, 0.77; 95% CI, 0.48 to 1.25) in the standard conditioning group. No outcomes differed significantly between groups. Grade 3 and 4 oral mucositis was less common in the RIC group (50 patients) than in the standard conditioning group (73 patients); the frequency of other adverse events such as GVHD and increased concentrations of bilirubin and creatinine did not differ significantly between groups.

A phase 2 single-center, randomized toxicity study (2013) compared MAC with RIC in patients who received allo-HCT to treat AML.⁴⁶ Adults 60 years of age or younger with AML were randomized (1:1) to treatment with RIC (n=18) or MAC (n=19) for allo-HCT. A maximum median mucositis grade of 1 was observed in the RIC group compared with grade 4 in the MAC group ($p<.001$). Hemorrhagic cystitis occurred in 8 (42%) of the patients in the MAC group and none (0%) in the RIC group ($p<.01$). Results of renal and hepatic tests did not differ significantly between groups. The RIC-treated patients had faster platelet engraftment ($p<.01$) and required fewer erythrocyte and platelet transfusions ($p<.001$) and less total parenteral nutrition than those treated with MAC ($p<.01$). Cytomegalovirus infection was more common in the MAC group (14/19) than in the RIC group (6/18; $p=.02$). Donor chimerism was similar in the 2 groups for CD19 and CD33 but was delayed for CD3 in the RIC group. Five-year treatment-related morbidity was approximately 11% in both groups, and rates of relapse and survival did not differ significantly. Patients in the MAC group with intermediate cytogenetic AML had a 3-year survival rate of 73% compared with 90% among those in the RIC group.

Comparative Trials

Russell et al (2022) published the results of an observational study of adults aged 60 to 70 years who underwent allo-HCT with RIC compared to patients who received only chemotherapy and did not undergo transplant.⁴⁷ A total of 932 patients with AML (not favorable risk) in remission were followed for 60 months, and 144 received allo-HCT with RIC. Five-year OS was 37% among transplant recipients. Allo-HCT with RIC led to improved OS compared to no transplant (37% vs. 20%, respectively; HR, 0.67; 95% CI, 0.53 to 0.84). Relapse-free survival was also improved with allo-HCT with RIC (32% vs. 13%, respectively).

In a 2016 comparative study by the European Society for Blood and Marrow Transplantation, long-term survival was evaluated among patients with AML who underwent allo-HCT with RIC or with MAC regimens.⁴⁸ Data from 701 patients receiving MAC and 722 patients receiving RIC were analyzed. Survival, relapse, and GVHD rates are summarized in Table 1. In a multivariate analysis, the following factors predicted nonrelapse mortality: RIC, age older than 55 years, advanced disease, and female donor to male recipient. Factors predicting chronic GVHD (a surrogate outcome for quality of life) were in vivo T-cell depletion, advanced disease, and peripheral blood cell transplantation.

Table 1. Comparison of 10-Year Outcomes for Reduced-Intensity Conditioning and Myeloablative Conditioning Regimens in Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Outcomes	RIC (n=722) Rate (95% CI), %	MAC (n=701) Rate (95% CI), %	p
Nonrelapse mortality	20 (17 to 24)	35 (31 to 39)	<.001
Relapse	48 (44 to 52)	34 (31 to 38)	<.001
Leukemia-free survival, overall	32 (28 to 35)	31 (27 to 35)	.57
Age 50 to 55 y	40 (33 to 46)	36 (32 to 41)	.32
Age >55 y	20 (14 to 26)	28 (24 to 32)	.02
Overall survival	35 (32 to 39)	33 (29 to 37)	.57
GVHD-free, relapse-free survival	21 (18 to 24)	22 (18 to 25)	.79

Adapted from Shimon et al (2016).⁴⁸

CI: confidence interval; GVHD: graft-versus-host disease; MAC: myeloablative conditioning; RIC: reduced-intensity conditioning.

In a comparative study by Bitan et al (2014), outcomes were compared for children with AML who underwent allo-HCT using RIC or MAC regimens.⁴⁹ A total of 180 patients were evaluated; 39 underwent RIC and 141 received MAC regimens. Univariate and multivariate analyses showed no significant differences in the rates of acute and chronic GVHD, leukemia-free survival, and OS between treatment groups. The 5-year probabilities of OS with RIC and MAC regimens were 45% and 48%, respectively ($p=.99$). Moreover, relapse rates were similar for RIC (39%) and MAC regimens (39%; $p=.95$), and recipients of MAC regimens were not at a higher risk for transplant-related mortality (16%) than recipients of RIC regimens (16%; $p=.73$).

Noncomparative Studies

In a phase 2 study by Devine et al (2015), 114 patients ages 60 to 74 years with AML in CR1 were treated with RIC and allo-HCT.⁵⁰ Patients were followed for 2 years. The primary endpoint was DFS, and secondary endpoints were nonrelapse mortality, GVHD, relapse, and OS. Two years after transplantation, the following rates were recorded: DFS, 42% (95% CI, 33% to 52%); OS, 48% (95% CI, 39% to 58%); nonrelapse mortality, 15% (95% CI, 8% to 21%); grades 2, 3, or 4 acute GVHD, 10% (95% CI, 4% to 15%); grades 2, 3, or 4 chronic GVHD, 28% (95% CI, 19% to 36%); and cumulative incidence of relapse, 44% (95% CI, 35% to 53%).

Section Summary: Allogeneic HCT With Reduced-Intensity Conditioning for Cytogenetic or Molecular Intermediate- or Poor-Risk AML in Remission

Evidence for the use of RIC and allo-HCT to treat patients with AML consists of 2 RCTs, 3 meta-analyses, and numerous comparative and noncomparative studies. In general, compared with MAC, RIC has comparable survival estimates (leukemia-free, overall), though relapse rates appear higher among patients receiving RIC in some studies.

**Autologous HCT for AML in Remission With Chemotherapy-Responsive Consolidation
Clinical Context and Therapy Purpose**

The purpose of autologous HCT in individuals with AML in remission who do not have a suitable allo-HCT donor is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with AML in remission who do not have a suitable allo-HCT donor.

Interventions

The therapy being considered is autologous HCT. For individuals with AML in remission without an acceptable allo-HCT donor, autologous HCT is an option for consolidation therapy.

Comparators

The following therapies are currently being used to make decisions about the treatment of AML in remission when no suitable allo-HCT donor is available: conventional chemotherapy.

Outcomes

The general outcomes of interest are survival outcomes (OS, DSS, and DFS), relapse rates, and treatment-related morbidity. The median survival of individuals with AML varies with several known prognostic factors related to individual and tumor characteristics such as age, performance status, and karyotype. Overall, the median survival for individuals with AML without chemotherapy or HCT is less than 10 months; the median survival in individuals with chemotherapy but without HCT is approximately 20 months.⁵ Individuals are followed up throughout their lifespan.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse effects, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Systematic Reviews

A meta-analysis published by Nathan et al (2004) compared survival outcomes for autologous HCT in CR1 with standard chemotherapy or no further treatment in AML patients ages 15 to 55 years.⁵¹ Two types of studies were eligible: (1) prospective cohort studies in which patients with an available sibling donor were offered allo-HCT (biologic randomization) with random assignment of all others to autologous HCT or chemotherapy (or no further treatment); and (2) randomized trials that compared autologous HCT with chemotherapy in all patients. Among a total of 4058 patients included in 6 studies, 2989 (74%) achieved CR1; 1044 (26%) were randomized to HCT (n=524) or to chemotherapy (n=520). Of the 5 studies for which OS data were available, outcomes with autologous HCT were better in 3, and outcomes with chemotherapy were better in 2. None of the differences were statistically significant, nor was the pooled estimate (fixed-effects model survival probability ratio, 1.01; 95% CI, 0.89 to 1.15; p=.86). In all 6 studies, DFS was numerically superior using autologous HCT compared with chemotherapy (or no further treatment), but only 1 reported a statistically significant DFS probability associated with autologous HCT. The pooled estimate for DFS showed a statistically significant probability in favor of autologous HCT at 48 months posttransplant (fixed-effects model survival probability ratio, 1.24; 95% CI, 1.06 to 1.44; p=.006). This review comprised studies performed between 1984 and 1995, during which transplant protocols and patient management evolved significantly, particularly compared with current care.

A second meta-analysis, published by Wang et al (2010), evaluated autologous HCT plus further chemotherapy or no further treatment for patients with AML in CR1.⁵² Nine randomized trials involving 1104 adults who underwent autologous HCT and 1118 patients who received additional chemotherapy or no additional treatment were identified. Analyses suggested that autologous HCT in CR1 is associated with a statistically significant reduction of relapse risk (relative risk, 0.56; 95% CI, 0.44 to 0.71; p=.001) and significant improvement in DFS (HR, 0.89; 95% CI, 0.80 to 0.98), but at the cost of an increased nonrelapse mortality rate (relative risk, 1.90; 95% CI, 1.34 to 2.70; p=.23). There were more deaths during the first remission among patients assigned to autologous HCT than among the chemotherapy recipients or further untreated patients. As a consequence of the increased nonrelapse mortality rate, no statistical difference in OS (HR, 1.05; 95% CI, 0.91 to 1.21) was associated with the use of autologous HCT, compared with further chemotherapy or no further therapy. These results are concordant with the earlier meta-analysis.

Randomized Controlled Trials

The RCTs published after the meta-analyses will be reviewed here.

A prospective, randomized phase 3 trial by Vellenga et al (2011) compared autologous HCT with intensive consolidation chemotherapy among patients (range, 16 to 60 years) with newly diagnosed AML of similar risk profiles in CR1.⁵³ After 2 cycles of intensive chemotherapy (etoposide and mitoxantrone), patients in CR1 who were not candidates for allo-HCT were randomized to a third consolidation cycle of the same chemotherapy (n=259) or autologous HCT (n=258). The HCT group experienced an upward trend toward superior RFS (38%) compared with the chemotherapy group at 5 years (29%; p=.065). The HCT patients also had a lower relapse rate at 5 years (58%) compared with chemotherapy recipients (70%; p=.02). The OS did not differ between the HCT group (44%) and the chemotherapy group (41%; p=.86). Nonrelapse mortality rates were higher in the autologous HCT group (4%) than in the chemotherapy consolidation group (1%; p=.02). Despite this difference in nonrelapse mortality, the relative equality of OS rates was attributed by the investigators to a higher proportion of successful salvage treatments (second-line chemotherapy, autologous or allo-HCT) in the chemotherapy consolidation recipients that were not available to the autologous HCT patients. This large trial has shown an advantage for post-remission autologous HCT in reducing relapse, but similar OS rates secondary to better salvage of chemotherapy-consolidated patients.

Miyamoto et al (2018) reported results of a randomized, multicenter phase 3 trial conducted in 24 centers in Japan from 2003 to 2011 that compared autologous HCT versus HiDAC consolidation as

post-remission therapy in AML.⁵⁴ This trial enrolled 240 patients between 15 and 64 years of age with newly diagnosed favorable- and intermediate-risk AML and Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3 ; 87 of those who achieved CR1 were randomized to autologous HCT or HiDAC. The study was powered to include 122 patients with 5 years of accrual and 3 years of post-accrual follow-up to detect a difference in DFS at 3 years of 40% versus 65%. Approximately one-third of the patients had favorable risk AML and the remaining two-thirds had intermediate-risk AML. The median age was 48 years. Median follow-up was approximately 4.5 to 5 years. Three-year DFS rate was 41% (95% CI, 27% to 55%) in the HiDAC group and 55% (95% CI, 38% to 68%) in the autologous HCT group ($p=.25$). Three-year OS was 77% (95% CI, 61% to 87%) versus 68% (95% CI, 52% to 80%) ($p=.67$). Cumulative incidence of relapse was 54% versus 41% ($p=.22$). There were no differences between the HiDAC and autologous HCT groups in the incidence of liver or renal dysfunction. The incidence of life-threatening infectious complications ($p=.003$) and mucositis/diarrhea ($p=.002$) was significantly higher in the autologous HCT group.

Section Summary: Autologous Hematopoietic Cell Transplant for AML in Remission With Chemotherapy-Responsive Consolidation

Evidence for the use of autologous HCT for patients with AML who do not have a suitable allogeneic donor or who cannot tolerate an allogeneic procedure consists of RCTs comparing autologous HCT with chemotherapy and prospective cohort studies. Meta-analyses of these studies and trials reported improved DFS and relapse but did not find a significant improvement in OS. A potential explanation for this discrepancy between DFS and OS is the increased nonrelapse mortality rate experienced by patients in the transplantation group.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society for Transplantation and Cellular Therapy

In 2020, the American Society for Transplantation and Cellular Therapy published expert panel recommendations on the role of hematopoietic cell transplant (HCT) in newly-diagnosed adult acute myeloid leukemia (AML).⁵⁵ Recommendations were generated based on findings from a systematic review and graded based on prespecified criteria. Expert panel recommendations regarding allogeneic HCT (allo-HCT) and autologous HCT and the grades of the recommendations are as follows:

- Patients with unfavorable-risk in first remission (CR1) should undergo allo-HCT. (Grade A)
- Patients with intermediate-risk in CR1 should undergo allo-HCT. (Grade B)
- Patients with favorable-risk in CR1 should not undergo allo-HCT. (Grade C)
- The role of secondary mutational abnormalities in selecting a patient for allo-HCT is unclear. (Grade N/A)
- The presence of measurable residual disease at the end of induction therapy should be considered an indication to offer allo-HCT. (Grade C)
- The role of allo-HCT is unclear in patients with induction failure. (Grade N/A [not applicable])
- Patients with secondary acute myeloid leukemia in CR1 should undergo allo-HCT. (Grade D)
- Patients with therapy-related acute myeloid leukemia in CR1 should undergo allo-HCT. (Grade D)
- Patients ≥ 60 years in CR1 should undergo allo-HCT. (Grade B)

- Autologous HCT is a good alternative to chemotherapy consolidation in patients who are not eligible for allo-HCT. (Grade B)
- Myeloablative conditioning should be the preferred type of conditioning in patients who are fit for myeloablative conditioning, but reduced-intensity conditioning is an acceptable alternative in unfit patients. (Grade D)

In 2015, the American Society for Transplantation and Cellular Therapy (formerly The American Society for Blood and Marrow Transplantation) published guidelines on indications for autologous HCT and allo-HCT.⁵⁶ An updated guideline was published in 2020.⁵⁷ Table 2 summarizes recommendations for HCT in AML from the most recent guideline iteration.

Table 2. Recommendations for the Use of Hematopoietic Cell Transplantation to Treat AML

Indication	Allo-HCT ^a	Autologous HCT ^a
AML, age <18 years		
First CR, low risk	N	N
First CR, intermediate risk	C	N
First CR, high risk	S	N
Second or greater CR	S	N
Not in remission	S	N
AML, age ≥18 years		
First CR, low risk	N	C
First CR, intermediate risk	S	C
First CR, high risk	S	N
Second CR	S	C
Third or greater CR	S	N
Not in remission	S	N

^a Recommendations were classified as follows: S, standard of care (well-defined and generally supported by evidence in the form of high quality clinical trials and/or observational studies); C, standard of care, clinical evidence available (large clinical trials are not available; however, sufficiently large cohort studies have shown efficacy with acceptable risk of morbidity and mortality); N, not generally recommended
 allo-HCT: allogeneic hematopoietic cell transplantation; AML: acute myeloid leukemia; CR: complete remission ; HCT: hematopoietic cell transplantation

In 2022, the American Society of Transplantation and Cellular Therapy published guidance on the role of HCT in pediatric AML and myelodysplastic syndrome.⁵⁸ The guidelines state that HCT is recommended for patients in CR1 with unfavorable mutations/cytomolecular abnormalities but not for patients with favorable-risk lesions. HCT should also be considered for patients with primary induction failure, refractory disease after 2 to 3 cycles of chemotherapy, and relapse.

National Comprehensive Cancer Network

The National Comprehensive Cancer Network clinical guidelines (v. 6.2023)² for AML state that allo-HCT is recommended for patients aged <60 years after standard-dose cytarabine induction with induction failure or significant residual disease without a hypocellular marrow. It is also recommended after high-dose cytarabine induction with induction failure, or as post-remission therapy in those with intermediate-risk or poor-risk cytogenetics. Allo-HCT is identified as a "reasonable option" for patients aged ≥60 years after standard-dose cytarabine induction with residual disease or induction failure or following complete response (preferably in a clinical trial). In addition, allo-HCT is recommended for relapsed or refractory disease.

According to the guidelines, the role of autologous HCT is diminishing due to improvements in allo-HCT that have expanded the pool of potential donors outside the family setting. Autologous HCT should not be a recommended consolidation therapy outside the setting of a clinical trial.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services have the following national coverage determination on the use of cell transplantation for AML ⁵⁹:

- Allogeneic: "...for the treatment of leukemia, leukemia in remission..."
- Autologous: "Acute leukemia in remission who have a high probability of relapse and who have no human leukocyte antigens (HLA)-matched."

Ongoing and Unpublished Clinical Trials

No clinical trials that would influence this review were found as of December 2023.

References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. *N Engl J Med*. Sep 17 2015; 373(12): 1136-52. PMID 26376137
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Version 6.2023. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Updated October 24, 2023. Accessed December 5, 2023.
3. Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: A primer. *Cancer*. Nov 01 2020; 126(21): 4668-4677. PMID 32767757
4. Koenig K, Mims A, Levis MJ, et al. The Changing Landscape of Treatment in Acute Myeloid Leukemia. *Am Soc Clin Oncol Educ Book*. Mar 2020; 40: 1-12. PMID 32239961
5. Master S, Mansour R, Devarakonda SS, et al. Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality. *Anticancer Res*. Apr 2016; 36(4): 1719-27. PMID 27069151
6. Masetti R, Muratore E, Gori D, et al. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. *Ann Hematol*. Nov 2022; 101(11): 2497-2506. PMID 36038660
7. Li D, Wang L, Zhu H, et al. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. *PLoS One*. 2015; 10(7): e0132620. PMID 26197471
8. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA*. Jun 10 2009; 301(22): 2349-61. PMID 19509382
9. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. *Cancer*. Apr 15 2005; 103(8): 1652-8. PMID 15742336
10. Baer MR, Greer JP. Acute myeloid leukemia in adults. In: Greer JP, Foerster J, Rodgers GM, et al., eds. *Wintrobe's Clinical Hematology* (12th ed.). Vol 2. Philadelphia: Lippincott Williams & Wilkins; 2009:1843-1888.
11. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. *Biol Blood Marrow Transplant*. May 2008; 14(5): 556-67. PMID 18410898
12. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. *Haematologica*. Nov 2006; 91(11): 1513-22. PMID 17082009
13. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. *Bone Marrow Transplant*. Mar 2008; 41(5): 415-23. PMID 18209726
14. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first

- remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? *Blood*. May 01 2007; 109(9): 3658-66. PMID 17213292
15. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2006: 169-77. PMID 17124057
 16. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. *J Clin Oncol*. Aug 20 2006; 24(24): 3904-11. PMID 16921041
 17. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. May 01 2008; 358(18): 1909-18. PMID 18450602
 18. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. *Haematologica*. May 2017; 102(5): 865-873. PMID 28126965
 19. Bornhäuser M, Schliemann C, Schetelig J, et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. *JAMA Oncol*. Apr 01 2023; 9(4): 519-526. PMID 36757706
 20. Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. *J Clin Oncol*. Feb 01 2014; 32(4): 288-96. PMID 24366930
 21. Heidrich K, Thiede C, Schäfer-Eckart K, et al. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. *Ann Oncol*. Nov 01 2017; 28(11): 2793-2798. PMID 28945881
 22. Begna KH, Kittur J, Gangat N, et al. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. *Blood Cancer J*. Jan 17 2022; 12(1): 7. PMID 35039473
 23. Wang ZY, Gao WH, Zhao HJ, et al. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis. *Acta Haematol*. 2022; 145(4): 419-429. PMID 35231903
 24. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2004: 98-117. PMID 15561679
 25. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol*. Mar 20 2005; 23(9): 1969-78. PMID 15632409
 26. Frazer J, Couban S, Doucette S, et al. Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. *Curr Oncol*. Apr 2017; 24(2): e123-e130. PMID 28490935
 27. Breems DA, Löwenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. *Semin Hematol*. Oct 2007; 44(4): 259-66. PMID 17961725
 28. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. *Cancer Control*. Oct 2011; 18(4): 237-45. PMID 21976242
 29. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. *Biol Blood Marrow Transplant*. Feb 2008; 14(2): 137-80. PMID 18215777
 30. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. Apr 2007; 92(4): 533-41. PMID 17488664
 31. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. *Biol Blood Marrow Transplant*. Feb 2008; 14(2): 181-6. PMID 18215778
 32. Valcárcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. *Curr Opin Oncol*. Nov 2007; 19(6): 660-6. PMID 17906468

33. Valcárcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. *J Clin Oncol.* Feb 01 2008; 26(4): 577-84. PMID 18086801
34. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *J Clin Oncol.* Jun 10 2010; 28(17): 2859-67. PMID 20439626
35. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. *J Clin Oncol.* Apr 10 2010; 28(11): 1878-87. PMID 20212255
36. Peffault de Latour R, Porcher R, Dalle JH, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. *Blood.* Dec 19 2013; 122(26): 4279-86. PMID 24144640
37. Hamidieh AA, Alimoghaddam K, Jahani M, et al. Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience. *J Pediatr Hematol Oncol.* Aug 2013; 35(6): e239-45. PMID 23042019
38. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. *J Clin Oncol.* Jan 20 2010; 28(3): 405-11. PMID 20008642
39. Pemmaraju N, Tanaka MF, Ravandi F, et al. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. *Clin Lymphoma Myeloma Leuk.* Aug 2013; 13(4): 485-92. PMID 23769669
40. Song Y, Yin Z, Ding J, et al. Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials. *Front Oncol.* 2021; 11: 708727. PMID 34692485
41. Rashidi A, Ebadi M, Colditz GA, et al. Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. *Biol Blood Marrow Transplant.* Apr 2016; 22(4): 651-657. PMID 26529178
42. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. *Stem Cells Dev.* Nov 01 2014; 23(21): 2535-52. PMID 25072307
43. Bornhäuser M, Kienast J, Trensche R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haematopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. *Lancet Oncol.* Oct 2012; 13(10): 1035-44. PMID 22959335
44. Scherwath A, Schirmer L, Kruse M, et al. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. *Psychooncology.* Jul 2013; 22(7): 1509-16. PMID 22945857
45. Shayegi N, Kramer M, Bornhäuser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. *Blood.* Jul 04 2013; 122(1): 83-92. PMID 23656730
46. Ringdén O, Erkers T, Aschan J, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. *J Intern Med.* Aug 2013; 274(2): 153-62. PMID 23432209
47. Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. *Haematologica.* Jul 01 2022; 107(7): 1518-1527. PMID 34647442
48. Shimoni A, Labopin M, Savani B, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with

- myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. *J Hematol Oncol.* Nov 08 2016; 9(1): 118. PMID 27821187
49. Bitan M, He W, Zhang MJ, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. *Blood.* Mar 06 2014; 123(10): 1615-20. PMID 24435046
 50. Devine SM, Owzar K, Blum W, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. *J Clin Oncol.* Dec 10 2015; 33(35): 4167-75. PMID 26527780
 51. Nathan PC, Sung L, Crump M, et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. *J Natl Cancer Inst.* Jan 07 2004; 96(1): 38-45. PMID 14709737
 52. Wang J, Ouyang J, Zhou R, et al. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. *Acta Haematol.* 2010; 124(2): 61-71. PMID 20616541
 53. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. *Blood.* Dec 01 2011; 118(23): 6037-42. PMID 21951683
 54. Miyamoto T, Nagafuji K, Fujisaki T, et al. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. *Int J Hematol.* Apr 2018; 107(4): 468-477. PMID 29243031
 55. Dholaria B, Savani BN, Hamilton BK, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. *Transplant Cell Ther.* Jan 2021; 27(1): 6-20. PMID 32966881
 56. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* Nov 2015; 21(11): 1863-1869. PMID 26256941
 57. Kanate AS, Majhail NS, Savani BN, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* Jul 2020; 26(7): 1247-1256. PMID 32165328
 58. Tarlock K, Sulis ML, Chewning JH, et al. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. *Transplant Cell Ther.* Sep 2022; 28(9): 530-545. PMID 35717004
 59. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Stem Cell Transplantation (Formerly 110.8.1) (110.23). 2016; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=366&ncdver=1&DocID=110.23&bc=gAAAAAgAAAAAAA%3D%3D&>. Accessed December 5, 2023.

Documentation for Clinical Review

Please provide the following documentation:

- History and physical from referring provider
- Bone marrow transplant consultation report and/or progress notes documenting:
 - Diagnosis (including disease staging) and prognosis
 - Specific transplant type being requested

- Synopsis of alternative treatments performed and results
- Surgical consultation report and/or progress notes
- Results of completed transplant evaluation including:
 - Clinical history including comorbidities
 - Consultation reports/letters (when applicable)
 - Correspondence from referring providers (when applicable)
 - Identification of donor for allogeneic related bone marrow/stem cell transplant (when information available)
 - Specific issues identified during the transplant evaluation
- Medical social service/social worker and/or psychiatric (if issues are noted) evaluations including psychosocial assessment or impression of patient's ability to be an adequate candidate for transplant
- Radiology reports including:
 - Chest x-ray (CXR)
 - PET scan, CT scan and bone survey (as appropriate)
- Cardiology procedures and pulmonary function reports:
 - Cardiac echocardiogram
 - EKG
 - Pulmonary function tests (PFTs)
- Biopsy/Pathology reports including:
 - Bone marrow biopsy; Lymph node biopsy (as appropriate)
- Laboratory report(s)

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

Type	Code	Description
CPT®	38204	Management of recipient hematopoietic progenitor cell donor search and cell acquisition
	38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
	38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
	38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage
	38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor
	38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor
	38210	Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion
	38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion

Type	Code	Description
	38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal
	38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion
	38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion
	38215	Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer
	38230	Bone marrow harvesting for transplantation; allogeneic
	38232	Bone marrow harvesting for transplantation; autologous
	38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
	38241	Hematopoietic progenitor cell (HPC); autologous transplantation
HCPCS	S2140	Cord blood harvesting for transplantation, allogeneic
	S2142	Cord blood-derived stem-cell transplantation, allogeneic
	S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
01/07/2011	BCBSA Medical Policy adoption
02/27/2015	Policy revision without position change
04/01/2016	Policy revision without position change
09/01/2017	Title change from Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Policy revision without position change.
01/01/2018	Coding update
03/01/2018	Policy revision without position change
03/01/2019	Policy revision without position change
11/01/2019	Policy revision without position change
04/01/2020	Annual review. No change to policy statement. Literature review updated.
03/01/2021	Annual review. Policy guidelines and Literature review updated.
04/01/2022	Annual review. No change to policy statement. Literature review updated.
04/01/2022	Annual review. No change to policy statement. Literature review updated.
04/01/2022	Annual review. No change to policy statement. Literature review updated.
10/01/2022	Administrative update.
04/01/2023	Annual review. Policy statement, guidelines and literature review updated.
04/01/2024	Annual review. No change to policy statement. Policy guidelines and literature review updated.

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<p>Hematopoietic Cell Transplantation for Acute Myeloid Leukemia 8.01.26</p> <p>Policy Statement:</p> <ol style="list-style-type: none"> I. Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat any of the following conditions: <ol style="list-style-type: none"> A. Poor- to intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) (see Policy Guidelines section for information on risk stratification) B. AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy C. AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy D. AML in individuals who have relapsed following a prior autologous HCT but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure II. Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in individuals who are in complete marrow and extramedullary remission (CR1 or beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines section). III. Autologous HCT may be considered medically necessary to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy in individuals who are not candidates for allogeneic HCT. 	<p>Hematopoietic Cell Transplantation for Acute Myeloid Leukemia 8.01.26</p> <p>Policy Statement:</p> <ol style="list-style-type: none"> I. Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat any of the following conditions: <ol style="list-style-type: none"> A. Poor- to intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) (see Policy Guidelines section for information on risk stratification) B. AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy C. AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy D. AML in individuals who have relapsed following a prior autologous HCT but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure II. Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in individuals who are in complete marrow and extramedullary remission (CR1 or beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines section). III. Autologous HCT may be considered medically necessary to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy in individuals who are not candidates for allogeneic HCT.

POLICY STATEMENT (No changes)	
BEFORE	AFTER
IV. Allogeneic and autologous HCT are considered investigational in individuals not meeting any of the above criteria.	IV. Allogeneic and autologous HCT are considered investigational in individuals not meeting any of the above criteria.